INSIGHTS & PROSPECTIVE

Clinical trials are the foundation of medical advancement. They bring new therapies to market, improve patient outcomes, and shape the future of healthcare. But behind every protocol, dataset, and regulatory submission is something far more important: The participant. And yet, in many cases, the participant’s voice is the least represented in the research process. This is where advocacy becomes essential. At Bridgepoint Clinical, we believe that advocacy is not an added layer

The push for diversity in clinical trials is no longer a conversation about intention. It is now a matter of expectation, accountability, and regulatory focus. With the release of updated guidance from the U.S. Food and Drug Administration, sponsors and research organizations are being called to take a more structured and measurable approach to ensuring that clinical trial populations reflect the patients who will ultimately use these therapies. This shift marks a pivotal mom

In today’s clinical research landscape, innovation is accelerating at an unprecedented pace. New therapies are being developed faster, trial designs are becoming more complex, and expectations for diversity and inclusion are higher than ever. Yet despite these advancements, one critical element continues to be overlooked: The participant experience. At Bridgepoint Clinical, we believe that participant insight is not a “nice to have.” It is a strategic necessity that directly